Skip to NavigationSkip to content

Novartis' Cosentyx gets European go-ahead in paediatric plaque psoriasis

Published on 03/08/20 at 11:47am

Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients between the ages of six and 18 with moderate-to-severe plaque psoriasis.

The ruling was secured on the back of data from two Phase 3 studies which demonstrated the safety and efficacy of low and high dosages (75-150mg and 75-300mg) in improving skin symptoms and quality of life. According to this latest approval, the recommended dose for children weighing up to 50 kg is 75 mg, and 150 mg for children 50 kg and over.

“Psoriasis is a life-long debilitating disease that significantly impacts children’s quality of life, both physically and emotionally. There are only a few approved treatment options available for the paediatric population and so it is important to broaden the adult therapeutic options out to children when possible,” said Professor Christine Bodemer, Head of the Department of Dermatology, Necker–Enfants Malades Hospital. “This approval means Cosentyx is now available in Europe for children and adolescents, and will provide an additional option to quickly gain relief from their symptom burden and to significantly improve their quality of life.”

Novartis said it was already at work in order to make the therapy available to eligible patients “as quickly as possible”.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches